NexImmune (NexImmune) EPS (Basic) : $-30.89 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NexImmune EPS (Basic)?

NexImmune's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-4.99. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.89.

NexImmune's EPS (Diluted) for the three months ended in Dec. 2023 was $-4.99. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-30.89.

NexImmune's EPS without NRI for the three months ended in Dec. 2023 was $-4.99. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -30.89.

During the past 3 years, the average EPS without NRI Growth Rate was 6.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, NexImmune's highest 3-Year average EPS without NRI Growth Rate was 6.80% per year. The lowest was -21.00% per year. And the median was -17.80% per year.

NexImmune EPS (Basic) Historical Data

The historical data trend for NexImmune's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune EPS (Basic) Chart

NexImmune Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-44.88

-41.92

-63.50

-64.95

-30.82

NexImmune Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial														-16.17	-9.25	-7.25	-9.40	-4.99

NexImmune EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

NexImmune's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-32.344	-	0)	/	1.049
	=	-30.83

NexImmune's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.359	-	0)	/	1.064
	=	-5.04

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.89

NexImmune (NAS:NEXI) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

NexImmune EPS (Basic) Related Terms

Thank you for viewing the detailed overview of NexImmune's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

NexImmune (NexImmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

9119 Gaither Road, Gaithersburg, MD, USA, 20877

Website

https://www.neximmune.com

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Executives

Alan S. Roemer	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover	officer: VP, Corporate Controller	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao	director	10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi	director	C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke	officer: Chief Science Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones	officer: Chief Operating Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis	officer: EVP of R&D	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer	director, officer: President and CEO	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer	officer: Chief Financial Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight	officer: Chief Medical Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877